Author

G. A. Stafford

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:variant calling· 1

Frequent Co-Authors

A. C. Grammer· 1 shared A. K. Simons· 1 shared A. R. Daamen· 1 shared A. Srivastava· 1 shared B. J. Sanderson· 1 shared C. G. Tepper· 1 shared C. J. Bult· 1 shared C. L. Mayberry· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. C. Grammer

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A Genomically and Clinically Annotated Patient Derived Xenograft (PDX) Resource for Preclinical Research in Non-Small Cell Lung Cancer

X. Y. Woo, A. Srivastava, P. C. Mack, J. H. Graber, B. J. Sanderson, M. W. Lloyd, M. Chen, S. Domanskyi, R. Gandour-Edwards, R. A. Tsai, J. Keck, M. Cheng, M. Bundy, E. L. Jocoy, J. W. Riess, , C. J. Bult

The paper describes a collection of 79 genomically and clinically annotated lung cancer PDX models that retain patient tumor features and treatment responses, available through MMHCdb.

bioRxiv · Mar 6, 2022Cancer Biology

Augmented glucose dependency of autoreactive B cells provides a treatment target forlupus

J. J. Wilson, J. Wei, A. R. Daamen, J. D. Sears, E. Bechtel, C. L. Mayberry, G. A. Stafford, L. Bechtold, A. C. Grammer, P. E. Lipsky, D. C. Roopenian, C.-H. Chang

This study identifies glycolysis-dependent autoreactive B cells as key mediators of lupus and shows that targeting them with 2DG or BCMA-specific CAR T-cells improves disease outcomes.

bioRxiv · Feb 1, 2022Immunology